Arecor Therapeutics PLC - Asset Resilience Ratio

Latest as of December 2025: 38.62%

Arecor Therapeutics PLC (AREC) has an Asset Resilience Ratio of 38.62% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of Arecor Therapeutics PLC to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

GBX3.13 Million

≈ $380.71 USD Cash + Short-term Investments

Total Assets

GBX8.10 Million

≈ $985.66 USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2022–2025)

This chart shows how Arecor Therapeutics PLC's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see AREC asset base.

Liquid Assets Composition Over Time

This chart breaks down Arecor Therapeutics PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read total liabilities of Arecor Therapeutics PLC for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	GBX0.00	0%
Short-term Investments	GBX3.13 Million	38.62%
Total Liquid Assets	GBX3.13 Million	38.62%

Asset Resilience Insights

Very High Liquidity: Arecor Therapeutics PLC maintains exceptional liquid asset reserves at 38.62% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Arecor Therapeutics PLC Industry Peers by Asset Resilience Ratio

Compare Arecor Therapeutics PLC's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Abivax SA PA:ABVX	Biotechnology	2.58%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Lifecome Biochemistry Co Ltd SHE:002868	Biotechnology	4.69%
Pulike Biological Engineering SHG:603566	Biotechnology	17.82%
Rocket Pharmaceuticals Inc NASDAQ:RCKT	Biotechnology	14.00%
NEWRON PHARMACEUT. EO-20 XETRA:NP5	Biotechnology	41.67%
Upstream Bio, Inc. NASDAQ:UPB	Biotechnology	64.70%

Annual Asset Resilience Ratio for Arecor Therapeutics PLC (2022–2025)

The table below shows the annual Asset Resilience Ratio data for Arecor Therapeutics PLC.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	38.62%	GBX3.13 Million ≈ $380.71	GBX8.10 Million ≈ $985.66	+38.42pp
2024-12-31	0.21%	GBX18.00K ≈ $2.19	GBX8.72 Million ≈ $1.06K	-10.58pp
2023-12-31	10.79%	GBX1.66 Million ≈ $201.85	GBX15.38 Million ≈ $1.87K	-26.16pp
2022-12-31	36.94%	GBX8.04 Million ≈ $978.36	GBX21.77 Million ≈ $2.65K	--

pp = percentage points

About Arecor Therapeutics PLC

LSE:AREC UK Biotechnology

Market Cap

$401.97K

GBX3.30 Billion GBX

Market Cap Rank

#31139 Global

#956 in UK

Share Price

GBX87.50

Change (1 day)

+0.00%

52-Week Range

GBX57.50 - GBX92.50

All Time High

GBX450.00